Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)
Authors:
- Julia M. NeuhannJNJulia M. Neuhann
- Jannik StemlerJSJannik Stemler
- Antonio J. CarcasACAntonio J. Carcas
- Murat AkovaMAMurat Akova
- Ullrich BetheUBUllrich Bethe
- Sarah HeringerSHSarah Heringer
- Jon Salmanton-GarcíaJSJon Salmanton-García
- Lea TischmannLTLea Tischmann
- Jan GrotheJGJan Grothe
Open Access
- 31 October 2023
- Vol. 41 (48) , 7166-7175
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 MonthsNew England Journal of Medicine, 2021
- Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational studyThe Lancet, 2021
- Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide surveyClinical Immunology, 2021
- BNT162b2 vaccine booster dose protection: A nationwide study from IsraelmedRxiv, 2021
- Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7Nature, 2021
- The conundrum of human immune system “senescence”Mechanisms of Ageing and Development, 2020
- The how’s and what’s of vaccine reactogenicitynpj Vaccines, 2019
- Vaccination in the elderly: The challenge of immune changes with agingSeminars in Immunology, 2018
- B-cell responses to vaccination at the extremes of ageNature Reviews Immunology, 2009
- The inflammatory response to vaccination is altered in the elderlyMechanisms of Ageing and Development, 2005